drugset / Trial / NCT06073132

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

NCT06073132

Phase 2/3 Active not recruiting 80 enrolled TWi Biotechnology, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The proposed Phase 2/3 trial with double-blind and open-label extension phases is an international, multicenter study designed to assess the efficacy and safety of diacerein 1% ointment in patients with generalized EBS.

Timeline

Start
2024-04-04
Primary completion
2026-06-10
Completion
2027-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Diacerein Small molecule 1 % Topical